OCULAR THERAPEUTIX, INC (OCUL) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $22.00K; Additional Paid in Capital, Common StockUSD $1.84B; Retained Earnings (Accumulated Deficit)USD $-1.32B; Stockholders' Equity Attributable to ParentUSD $520.04M.
- 2026-03-31: Common Stock, Value, IssuedUSD $22.00K; Additional Paid in Capital, Common StockUSD $1.83B; Retained Earnings (Accumulated Deficit)USD $-1.25B; Stockholders' Equity Attributable to ParentUSD $581.57M.
- 2025-12-31: Common Stock, Value, IssuedUSD $22.00K; Additional Paid in Capital, Common StockUSD $1.81B; Retained Earnings (Accumulated Deficit)USD $-1.16B; Stockholders' Equity Attributable to ParentUSD $654.31M.
- 2025-09-30: Common Stock, Value, IssuedUSD $18.00K; Additional Paid in Capital, Common StockUSD $1.35B; Retained Earnings (Accumulated Deficit)USD $-1.09B; Stockholders' Equity Attributable to ParentUSD $258.23M.
OCULAR THERAPEUTIX, INC Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $22.00K | $1.84B | $-1.32B | $520.04M | 3 month · $14.65M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $22.00K | $1.83B | $-1.25B | $581.57M | 3 month · $15.58M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $22.00K | $1.81B | $-1.16B | $654.31M | 12 month · $43.18M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $18.00K | $1.35B | $-1.09B | $258.23M | 3 month · $11.69M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $17.00K | $1.33B | $-1.02B | $305.92M | 3 month · $9.68M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $16.00K | $1.22B | $-955.14M | $265.93M | 3 month · $10.46M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $16.00K | $1.21B | $-891.08M | $315.34M | 12 month · $33.11M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $16.00K | $1.19B | $-842.70M | $352.02M | 3 month · $6.64M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $16.00K | $1.18B | $-806.20M | $377.69M | 3 month · $11.29M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $15.00K | $1.17B | $-762.43M | $407.98M | 3 month · $7.98M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $12.00K | $788.70M | $-697.58M | $91.13M | 12 month · $17.82M | (m) | (m) | (m) | (m) |
| 2023-09-30 | $8.00K | $676.20M | $-668.36M | $7.85M | 3 month · $4.51M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $8.00K | $670.92M | $-667.84M | $3.09M | 3 month · $4.41M | (m) | (m) | (m) | (m) |
| 2023-03-31 | $8.00K | $656.86M | $-647.16M | $9.71M | 3 month · $4.57M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $8.00K | $652.21M | $-616.84M | $35.38M | 12 month · $16.96M | (m) | (m) | (m) | (m) |
| 2022-09-30 | $8.00K | $647.52M | $-601.30M | $46.23M | 3 month · $4.24M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $8.00K | $642.91M | $-577.11M | $65.80M | 3 month · $4.28M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $8.00K | $638.13M | $-558.35M | $79.80M | 3 month · $4.21M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $8.00K | $633.79M | $-545.80M | $88.00M | 12 month · $14.98M | (m) | (m) | 12 month · $91.00K | (m) |
| 2021-09-30 | $8.00K | $629.29M | $-541.95M | $87.34M | 3 month · $3.76M | (m) | (m) | (m) | (m) |
| 2021-06-30 | $8.00K | $624.85M | $-544.61M | $80.25M | 3 month · $4.29M | (m) | (m) | (m) | (m) |
| 2021-03-31 | $8.00K | $619.53M | $-536.13M | $83.41M | 3 month · $3.09M | (m) | (m) | 3 month · $91.00K | (m) |
| 2020-12-31 | $8.00K | $615.34M | $-539.25M | $76.09M | 12 month · $7.53M | (m) | (m) | (m) | (m) |
| 2020-09-30 | $6.00K | $449.51M | $-453.64M | $-4.13M | 3 month · $1.94M | (m) | (m) | (m) | (m) |
| 2020-06-30 | $6.00K | $447.03M | $-441.69M | $5.34M | 3 month · $1.83M | (m) | (m) | (m) | (m) |
| 2020-03-31 | $5.00K | $394.46M | $-405.13M | $-10.66M | 3 month · $1.67M | (m) | (m) | (m) | (m) |
| 2019-12-31 | $5.00K | $379.98M | $-383.62M | $-3.63M | 12 month · $8.76M | (m) | (m) | (m) | (m) |
| 2019-09-30 | $5.00K | $368.89M | $-357.60M | $11.30M | 3 month · $3.17M | (m) | (m) | (m) | (m) |
| 2019-06-30 | $4.00K | $347.07M | $-338.82M | $8.26M | 3 month · $1.70M | (m) | (m) | (m) | (m) |
| 2019-03-31 | $4.00K | $340.01M | $-314.37M | $25.65M | 3 month · $1.94M | (m) | (m) | (m) | (m) |
| 2018-12-31 | $4.00K | $333.11M | $-297.24M | $35.88M | 12 month · $7.48M | (m) | (m) | (m) | (m) |
| 2018-09-30 | $4.00K | $325.36M | $-279.84M | $45.52M | 3 month · $1.87M | (m) | (m) | (m) | (m) |
| 2018-06-30 | $4.00K | $310.56M | $-264.83M | $45.73M | 3 month · $1.83M | (m) | (m) | (m) | (m) |
| 2018-03-31 | $4.00K | $300.21M | $-251.03M | $49.18M | 3 month · $1.83M | (m) | (m) | (m) | (m) |
| 2017-12-31 | $3.00K | $263.41M | $-237.26M | $26.15M | 12 month · $7.32M | (m) | (m) | (m) | (m) |
| 2017-09-30 | $3.00K | $260.08M | $-224.16M | $35.92M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $3.00K | $256.62M | $-208.60M | $48.02M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $3.00K | $253.81M | $-189.90M | $63.91M | (m) | (m) | $-9.00K | (m) | (m) |
| 2016-12-31 | $3.00K | $225.89M | $-173.88M | $52.01M | 12 month · $5.96M | (m) | $-5.00K | 12 month · $245.00K | (m) |
| 2016-09-30 | $2.00K | $223.34M | $-161.06M | $62.29M | (m) | (m) | $5.00K | (m) | (m) |
| 2016-06-30 | $2.00K | $221.90M | $-151.46M | $70.45M | (m) | (m) | $10.00K | (m) | (m) |
| 2016-03-31 | $2.00K | $220.18M | $-140.02M | $80.17M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $2.00K | $218.83M | $-129.18M | $89.59M | 12 month · $4.64M | (m) | $-68.00K | 12 month · $564.00K | (m) |
| 2015-09-30 | $2.00K | $217.36M | $-118.54M | $98.81M | (m) | (m) | $-16.00K | (m) | (m) |
| 2015-06-30 | $2.00K | $216.13M | $-107.02M | $109.11M | (m) | (m) | $-8.00K | (m) | (m) |
| 2015-03-31 | $2.00K | $149.08M | $-97.01M | $52.07M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $2.00K | $148.12M | $-89.43M | $58.70M | 12 month · $2.64M | (m) | (m) | 12 month · $3.11M | (m) |
| 2014-09-30 | $2.00K | (m) | $-81.47M | $65.60M | (m) | $147.07M | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $-74.18M | $-69.44M | (m) | $4.75M | (m) | (m) | 6 month · $326.00K |
| 2013-12-31 | (m) | $1.31M | $-60.78M | $-59.47M | 12 month · $476.00K | $1.31M | (m) | 12 month · $6.00K | (m) |
| 2012-12-31 | (m) | (m) | (m) | $-46.61M | 12 month · $-243.00K | (m) | (m) | 12 month · $6.00K | (m) |
| 2011-12-31 | (m) | (m) | (m) | $-32.73M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |